{
  "metadata": {
    "title": "Primidone oxidation catalyzed by metalloporphyrins and Jacobsen catalyst",
    "authors": "; ; ",
    "journal": "Journal of Molecular Catalysis A: Chemical",
    "date": "2008-12-10",
    "doi": "10.1016/j.molcata.2008.09.008",
    "abstract": "",
    "uri": "https://api.elsevier.com/content/article/pii/S1381116908004007",
    "pii": "S1381116908004007"
  },
  "fulltext": {
    "full-text-retrieval-response": {
      "scopus-eid": "2-s2.0-55549117092",
      "originalText": "serial JL 271358 291210 291744 291790 291809 31 Journal of Molecular Catalysis A: Chemical JOURNALMOLECULARCATALYSISACHEMICAL 2008-09-18 2008-09-18 2010-03-29T10:57:16 1-s2.0-S1381116908004007 S1381-1169(08)00400-7 S1381116908004007 10.1016/j.molcata.2008.09.008 S300 S300.1 FULL-TEXT 1-s2.0-S1381116908X00159 2015-05-15T05:56:33.307883-04:00 0 0 20081210 2008 2008-09-18T00:00:00Z articleinfo crossmark dco dateupdated tomb dateloaded datesearch indexeddate issuelist volumelist yearnav absattachment articletitlenorm authfirstinitialnorm authfirstsurnamenorm cid cids contenttype copyright dateloadedtxt docsubtype doctype doi eid ewtransactionid hubeid issfirst issn issnnorm itemstage itemtransactionid itemweight openaccess openarchive pg pgfirst pglast pii piinorm pubdatestart pubdatetxt pubyr sortorder srctitle srctitlenorm srctype subheadings volfirst volissue webpdf webpdfpagecount figure table body acknowledge affil articletitle auth authfirstini authfull authkeywords authlast primabst ref specialabst alllist content subj ssids 1381-1169 13811169 296 296 1 2 1 2 Volume 296, Issues 1–2 10 54 60 54 60 20081210 10 December 2008 2008-12-10 2008 article fla Copyright © 2008 Elsevier B.V. All rights reserved. PRIMIDONEOXIDATIONCATALYZEDBYMETALLOPORPHYRINSJACOBSENCATALYST MACLEOD T 1 Introduction 2 Experimental 2.1 Materials and equipment 2.2 Oxidation reactions 3 Results and discussion 4 Conclusion Acknowledgements References MATSUO 2008 78 A LIVINGSTONE 1998 43 D KLEINOW 1987 105 K MANSUY 2007 392 D KIM 2007 213 D MONTELLANO 2004 P CYTOCHROMEP450STRUCTUREMECHANISMBIOCHEMISTRY DENISOV 2005 2253 I GROVES 1997 6269 J HUBIN 2000 2512 T FARIA 2008 863 A CHORGHADE 1996 753 M VIDAL 1993 811 M BERNADOU 1991 360 J SANTOS 2005 326 A KOMURO 1996 2309 M MELO 2005 23 A BERNADOU 2004 171 J JACOBSEN 1991 7063 E YAN 2002 10065 S KATSUKI 1996 87 T KATSUKI 1995 189 T IRIE 1991 481 R MACLEOD 2006 319 T MIRKHANI 2006 221 V GRAY 1996 191 H MACLEOD 2007 259 T MANDRIOLI 2001 109 R KONSIL 2002 169 J FERRANTI 1998 199 V GARERI 1999 389 P ELMASRI 1998 585 H ADLER 1970 2443 A SHAREFKIN 1963 62 J LAFONT 1990 61 O FOLTZ 1972 294 R ANDRESEN 1976 21 B ANDRESEN 1977 439 451 B MEUNIER 1992 1411 B GUNTER 1991 121 M BATTIONI 1988 8462 P VENKATARAMANAN 2005 1249 N NAM 2000 8677 W NAM 1999 387 W ALTARAKJIKHALFHL 1993 593 Y MACLEODX2008X54 MACLEODX2008X54X60 MACLEODX2008X54XT MACLEODX2008X54X60XT item S1381-1169(08)00400-7 S1381116908004007 1-s2.0-S1381116908004007 10.1016/j.molcata.2008.09.008 271358 2010-10-11T07:06:48.629223-04:00 2008-12-10 1-s2.0-S1381116908004007-main.pdf https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1381116908004007/MAIN/application/pdf/65afb404f756fafcdbf6d1c5de8b0e27/main.pdf https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1381116908004007/MAIN/application/pdf/65afb404f756fafcdbf6d1c5de8b0e27/main.pdf main.pdf pdf true 491022 MAIN 7 1-s2.0-S1381116908004007-main_1.png https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1381116908004007/PREVIEW/image/png/0a9cb09f9da4676cf896a3a392dc8660/main_1.png https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1381116908004007/PREVIEW/image/png/0a9cb09f9da4676cf896a3a392dc8660/main_1.png main_1.png png 57759 849 656 IMAGE-WEB-PDF 1 1-s2.0-S1381116908004007-gr4.jpg https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1381116908004007/gr4/DOWNSAMPLED/image/jpeg/6a5f301fbdc64a2ca3695ccf6ab5a787/gr4.jpg https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1381116908004007/gr4/DOWNSAMPLED/image/jpeg/6a5f301fbdc64a2ca3695ccf6ab5a787/gr4.jpg gr4 gr4.jpg jpg 17703 201 376 IMAGE-DOWNSAMPLED 1-s2.0-S1381116908004007-gr4.sml https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1381116908004007/gr4/THUMBNAIL/image/gif/446d96078901c2e4c0af38f13a3413db/gr4.sml https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1381116908004007/gr4/THUMBNAIL/image/gif/446d96078901c2e4c0af38f13a3413db/gr4.sml gr4 gr4.sml sml 1891 67 125 IMAGE-THUMBNAIL 1-s2.0-S1381116908004007-gr5.jpg https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1381116908004007/gr5/DOWNSAMPLED/image/jpeg/d330df3d328919ae22d0caf9e64de663/gr5.jpg https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1381116908004007/gr5/DOWNSAMPLED/image/jpeg/d330df3d328919ae22d0caf9e64de663/gr5.jpg gr5 gr5.jpg jpg 22237 200 376 IMAGE-DOWNSAMPLED 1-s2.0-S1381116908004007-gr5.sml https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1381116908004007/gr5/THUMBNAIL/image/gif/769e2cc0c08778b647c14955996e599a/gr5.sml https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1381116908004007/gr5/THUMBNAIL/image/gif/769e2cc0c08778b647c14955996e599a/gr5.sml gr5 gr5.sml sml 2189 66 125 IMAGE-THUMBNAIL 1-s2.0-S1381116908004007-gr6.jpg https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1381116908004007/gr6/DOWNSAMPLED/image/jpeg/73cf63abe145d6d84d18756c64fec1a3/gr6.jpg https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1381116908004007/gr6/DOWNSAMPLED/image/jpeg/73cf63abe145d6d84d18756c64fec1a3/gr6.jpg gr6 gr6.jpg jpg 18218 190 376 IMAGE-DOWNSAMPLED 1-s2.0-S1381116908004007-gr6.sml https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1381116908004007/gr6/THUMBNAIL/image/gif/ff288397071fd35ebbfbf8fb8696cd30/gr6.sml https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1381116908004007/gr6/THUMBNAIL/image/gif/ff288397071fd35ebbfbf8fb8696cd30/gr6.sml gr6 gr6.sml sml 1652 63 125 IMAGE-THUMBNAIL 1-s2.0-S1381116908004007-gr7.jpg https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1381116908004007/gr7/DOWNSAMPLED/image/jpeg/ac8a981b6d41d9280420e0d1fbdb67e1/gr7.jpg https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1381116908004007/gr7/DOWNSAMPLED/image/jpeg/ac8a981b6d41d9280420e0d1fbdb67e1/gr7.jpg gr7 gr7.jpg jpg 23096 199 376 IMAGE-DOWNSAMPLED 1-s2.0-S1381116908004007-gr7.sml https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1381116908004007/gr7/THUMBNAIL/image/gif/2217b7eb231a52bc5f809c2160ea9d64/gr7.sml https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1381116908004007/gr7/THUMBNAIL/image/gif/2217b7eb231a52bc5f809c2160ea9d64/gr7.sml gr7 gr7.sml sml 2331 66 125 IMAGE-THUMBNAIL 1-s2.0-S1381116908004007-gr10.jpg https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1381116908004007/gr10/DOWNSAMPLED/image/jpeg/39e4ecdeef968d9d7cafdf4beb95ffa1/gr10.jpg https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1381116908004007/gr10/DOWNSAMPLED/image/jpeg/39e4ecdeef968d9d7cafdf4beb95ffa1/gr10.jpg gr10 gr10.jpg jpg 17423 203 368 IMAGE-DOWNSAMPLED 1-s2.0-S1381116908004007-gr10.sml https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1381116908004007/gr10/THUMBNAIL/image/gif/8ca2bb6871e50de0a126cbd7897bd00d/gr10.sml https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1381116908004007/gr10/THUMBNAIL/image/gif/8ca2bb6871e50de0a126cbd7897bd00d/gr10.sml gr10 gr10.sml sml 1732 69 125 IMAGE-THUMBNAIL 1-s2.0-S1381116908004007-gr11.jpg https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1381116908004007/gr11/DOWNSAMPLED/image/jpeg/b586b40d3f3aa666404aa7bdeabba37e/gr11.jpg https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1381116908004007/gr11/DOWNSAMPLED/image/jpeg/b586b40d3f3aa666404aa7bdeabba37e/gr11.jpg gr11 gr11.jpg jpg 23648 200 376 IMAGE-DOWNSAMPLED 1-s2.0-S1381116908004007-gr11.sml https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1381116908004007/gr11/THUMBNAIL/image/gif/eb19eacb5bfe5b9fafc10b18d26d9b7d/gr11.sml https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1381116908004007/gr11/THUMBNAIL/image/gif/eb19eacb5bfe5b9fafc10b18d26d9b7d/gr11.sml gr11 gr11.sml sml 2421 66 125 IMAGE-THUMBNAIL 1-s2.0-S1381116908004007-gr1.gif https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1381116908004007/gr1/DOWNSAMPLED/image/gif/cb575ee9e5caed9aaa520db3b625c393/gr1.gif https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1381116908004007/gr1/DOWNSAMPLED/image/gif/cb575ee9e5caed9aaa520db3b625c393/gr1.gif gr1 gr1.gif gif 9986 263 508 IMAGE-DOWNSAMPLED 1-s2.0-S1381116908004007-gr1.sml https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1381116908004007/gr1/THUMBNAIL/image/gif/db4b3203a61c63d07c63c9ee219d9026/gr1.sml https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1381116908004007/gr1/THUMBNAIL/image/gif/db4b3203a61c63d07c63c9ee219d9026/gr1.sml gr1 gr1.sml sml 1257 65 125 IMAGE-THUMBNAIL 1-s2.0-S1381116908004007-gr2.gif https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1381116908004007/gr2/DOWNSAMPLED/image/gif/3ddc43593d8e6b7fd555b401770c2aea/gr2.gif https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1381116908004007/gr2/DOWNSAMPLED/image/gif/3ddc43593d8e6b7fd555b401770c2aea/gr2.gif gr2 gr2.gif gif 14148 485 659 IMAGE-DOWNSAMPLED 1-s2.0-S1381116908004007-gr2.sml https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1381116908004007/gr2/THUMBNAIL/image/gif/c16440ba6304d37a82ac7cfe7f4efbdd/gr2.sml https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1381116908004007/gr2/THUMBNAIL/image/gif/c16440ba6304d37a82ac7cfe7f4efbdd/gr2.sml gr2 gr2.sml sml 1283 92 125 IMAGE-THUMBNAIL 1-s2.0-S1381116908004007-gr3.gif https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1381116908004007/gr3/DOWNSAMPLED/image/gif/31e4b027d1f48305c855a9f363a33906/gr3.gif https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1381116908004007/gr3/DOWNSAMPLED/image/gif/31e4b027d1f48305c855a9f363a33906/gr3.gif gr3 gr3.gif gif 6427 120 602 IMAGE-DOWNSAMPLED 1-s2.0-S1381116908004007-gr3.sml https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1381116908004007/gr3/THUMBNAIL/image/gif/224f0260812dfa0446fddd5b39a7ced1/gr3.sml https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1381116908004007/gr3/THUMBNAIL/image/gif/224f0260812dfa0446fddd5b39a7ced1/gr3.sml gr3 gr3.sml sml 671 25 125 IMAGE-THUMBNAIL 1-s2.0-S1381116908004007-gr8.gif https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1381116908004007/gr8/DOWNSAMPLED/image/gif/dfedcd6274afbe4e0b22c3e71f23a312/gr8.gif https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1381116908004007/gr8/DOWNSAMPLED/image/gif/dfedcd6274afbe4e0b22c3e71f23a312/gr8.gif gr8 gr8.gif gif 7410 171 753 IMAGE-DOWNSAMPLED 1-s2.0-S1381116908004007-gr8.sml https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1381116908004007/gr8/THUMBNAIL/image/gif/4e92b9535a883f5f50b9ca6cd9ed65ee/gr8.sml https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1381116908004007/gr8/THUMBNAIL/image/gif/4e92b9535a883f5f50b9ca6cd9ed65ee/gr8.sml gr8 gr8.sml sml 536 28 125 IMAGE-THUMBNAIL 1-s2.0-S1381116908004007-gr9.gif https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1381116908004007/gr9/DOWNSAMPLED/image/gif/39ca083ed85b0220ea59ff796ea65e1e/gr9.gif https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1381116908004007/gr9/DOWNSAMPLED/image/gif/39ca083ed85b0220ea59ff796ea65e1e/gr9.gif gr9 gr9.gif gif 6814 137 719 IMAGE-DOWNSAMPLED 1-s2.0-S1381116908004007-gr9.sml https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1381116908004007/gr9/THUMBNAIL/image/gif/0c87eee2a9bf337611687995a101ef39/gr9.sml https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1381116908004007/gr9/THUMBNAIL/image/gif/0c87eee2a9bf337611687995a101ef39/gr9.sml gr9 gr9.sml sml 578 24 125 IMAGE-THUMBNAIL 1-s2.0-S1381116908004007-fx1.gif https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1381116908004007/fx1/DOWNSAMPLED/image/gif/3a88eb6784e7de3afc2819421180d64b/fx1.gif https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1381116908004007/fx1/DOWNSAMPLED/image/gif/3a88eb6784e7de3afc2819421180d64b/fx1.gif fx1 true fx1.gif gif 3440 105 448 IMAGE-DOWNSAMPLED 1-s2.0-S1381116908004007-fx1.sml https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1381116908004007/fx1/THUMBNAIL/image/gif/43c03330d77920762968c33fe1d62093/fx1.sml https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1381116908004007/fx1/THUMBNAIL/image/gif/43c03330d77920762968c33fe1d62093/fx1.sml fx1 true fx1.sml sml 1193 51 219 IMAGE-THUMBNAIL MOLCAA 7264 S1381-1169(08)00400-7 10.1016/j.molcata.2008.09.008 Elsevier B.V. Fig. 1 In vivo metabolism of primidone. PRM: primidone; PRM-OH: 2-hydroxyprimidone; FENO: phenobarbital; PEMA: phenylethylmalondiamide. Fig. 2 Metallopophyrins and the salen complex used in this study (M=FeIII or MnIII). M(TCPP)Cl: 5,10,15,20-tetrakis(4-carboxyphenyl)porphyrin metal (III) chloride (metal: Fe or Mn); Mn(TFPP)Cl: 5,10,15,20-tetrakis(pentafluorophenyl)porphyrin manganese (III) chloride; Mn(salen): Jacobsen catalyst or (R,R)-(−)-N,N-bis(3,5-di-tert-butylsalicylidene)-1,2-cyclohexanediamine manganese(III) chloride. Fig. 3 Chemical structure of primidone and the metabolites identified in this work. PRM: primidone; FENO: Phenobarbital; PEMA: phenylethylmalondiamide; PBA: 2-phenylbutyramide; BL: α-phenyl-γ-butyrolactone. Fig. 4 Product distribution, as percentage, obtained in the Mn(salen)-catalyzed PRM oxidation by t-BOOH in ACN in air atmosphere and in the absence of dioxygen (argon atmosphere). PD 3 is an unknown product. Fig. 5 Product distribution, as percentage, obtained in the Mn(salen)-catalyzed PRM oxidation by t-BOOH in ACN, in the standard conditions (cond 1) and in excess oxidant (cond 2). PD 3 is an unknown product. Fig. 6 Product distribution, as percentage, obtained in the Mn(salen)-catalyzed PRM oxidation by t-BOOH in ACN in the standard conditions and in the presence of imidazole. PD 3 is an unknown product. Fig. 7 Product distribution, as percentage, obtained in the Mn(salen)-catalyzed PRM oxidation by t-BOOH in buffered aqueous solution/ACN 1:1 at different pH values. PD 3 is an unknown product. Fig. 8 Scheme for Mn(salen)-catalyzed primidone oxidation. Fig. 9 Mechanism of the formation of BL (α-phenyl-γ-butyrolactone), adapted from Al-Tarakji-Khalfhl et al. [44]. Fig. 10 Total yield of the metalloporphyrin-catalyzed PRM oxidation reactions compared with the Mn(salen)-catalyzed reaction. Fig. 11 Product distribution, as percentage, obtained with different catalysts in PRM oxidation by t-BOOH. Solvent=ACN for MnTFPP and Mn(salen); solvent=aqueous medium/ACN 1:1 for MnTCPP and FeTCPP. Table 1 Results obtained for primidone oxidation reactions catalyzed by Mn(salen) with different oxidants (m-CPBA, t-BOOH, H2O2). Entry Product R (%) m-CPBA t-BOOH H2O2 1 PEMA 31 23 27 2 FENO 2 9 5 3 PD 1 12 14 14 4 PD 2 Trace Trace Trace 5 PD 3 Trace Trace Trace Catalyst/substrate/oxidant molar ratio=1:40:35; blank reactions (absence of catalyst): no products detected; reaction time=6h; yield R (%) based on added substrate; PD 1, PD 2 and PD 3 are unknown products and the yields for these products were calculated by estimating the average response factor for known products. Table 2 Main fragments of the products PD 1 (PBA) and PD 2 (BL) generated during the oxidation of primidone as determined by GC–MS. Compound Molecular ion Fragments (m/z) PD 1 (PBA) (2-phenylbutyramide) 163 163 (17%), 148 (7%), 135 (24%), 119 (20%), 91 (100%), 78 (12%), 65 (10%) PD 2 (BL) (α-phenyl-γ-butyrolactone) 162 162 (100%), 133 (10%), 117 (69%), 107 (98%), 91 (33%), 77 (72%), 56 (100%), 51 (52%) Table 3 Total product yield obtained for primidone oxidation reactions catalyzed by Mn(salen) in the standard conditions (1) and in excess oxidant (2). Entry Oxidant R (%) a 1 t-BOOH b 45 2 t-BOOH c 58 a Yield R (%) based on added substrate. b Catalyst/substrate/oxidant molar ratio=1:40:35. c Catalyst/substrate/oxidant molar ratio=1:150:30; blank reactions (absence of catalyst): no products detected; reaction time=6h. Primidone oxidation catalyzed by metalloporphyrins and Jacobsen catalyst T.C.O. Mac Leod A.L. Faria V.P. Barros M.E.C. Queiroz M.D. Assis ⁎ Departamento de Química - Faculdade de Filosofia, Ciências e Letras de Ribeirão Preto - Universidade de São Paulo - Av. Bandeirantes 3900, 14040-901 Ribeirão Preto - SP, Brazil ⁎ Corresponding author. Tel.: +55 16 3602 3799; fax: +55 16 3602 4838. Primidone (PRM) oxidation by various oxidants such as iodosylbenzene (PhIO), tert-butyl hydroperoxide 70wt.% (t-BOOH), 3-chloroperoxybenzoic acid (m-CPBA) and hydrogen peroxide 30wt.%, mediated by either a salen complex or metalloporphyrins, was investigated. The catalytic systems led to phenylethylmalondiamide (PEMA) and phenobarbital (FENO), the same metabolites obtained in vivo with P450 enzymes, although three other products were also detected. Product formation was highly dependent on the oxidant, co-catalyst (imidazole), pH and dioxygen. These biomimetic chemical models have potential application in the synthesis of drug metabolites, which should provide samples for pharmacological tests. They can also be employed in studies that pursue the elucidation of in vivo drug metabolism. Graphical abstract Primidone (PRM) oxidation by various oxidants such as iodosylbenzene (PhIO), tert-butyl hydroperoxide 70wt.% (t-BOOH), 3-chloroperoxybenzoic acid (m-CPBA) and hydrogen peroxide 30wt.%, mediated by either a salen complex or metalloporphyrins, was investigated. The catalytic systems led to the same metabolites phenylethylmalondiamide (PEMA) and phenobarbital (FENO) obtained in vivo with P450 enzymes, although three other products were also detected. Keywords Primidone Salen complex Metalloporphyrin Catalysis Biomimetic models Jacobsen catalyst 1 Introduction Metabolic processes aim at converting drugs into less biologically active intermediates. After being absorbed, xenobiotics spread through the organism, where they either exert some sort of action or become the target of metabolic mechanisms. These mechanisms can make drugs less harmful; however, they can also bioactivate xenobiotics, leading to toxicity. The biotransformation of drugs comprises two phases. Phase I promotes changes to the original shape of the molecule, as in the case of the addition of a functional group, which includes oxidation, hydrolysis and reduction reactions. Phase I enables the occurrence of Phase II, which consists of a conjugation step [1–3]. The objective of Phases I and II is to render the compound more polar, which should facilitate its elimination from the body. The cytochrome P450 monoxygenases are among the various enzymatic systems responsible for metabolic processes. The P450 enzymes belong to a superfamily of hemeproteins that are ubiquitous in all living organisms, and they are involved in the metabolism of a wide variety of chemical compounds [4–7]. In the presence of oxygen donors, synthetic metalloporphyrins are known to mimic the various reactions of cytochrome P450 enzymes, such as the oxidation and oxygenation of various drugs and biologically active compounds. Some examples include carbamazepine [8–10], lidocaine, odapipam, aminopyrine [11], acetaminophen [12,13], chloroquine [14], among others [15,16]. Recent reviews by Bernadou and Meunier [17], and Mansuy [4] have compiled most of these studies. Salen complexes have attracted researchers’ attention as promising catalysts for the selective oxidation of organic molecules, which should lead to the preparation of novel compounds in both chemical and pharmaceutical industries [18–24]. These catalysts can also form complexes that mimic metalloporphyrin chemistry, so they can be employed to mimic the action of cytochrome P450 in drug metabolism [25,26]. Because reports on the use of salen complexes for drug oxidation are rare in the literature, this has been the focus of our research. In a previous work, we reported the salen-catalyzed selective oxidation of the antiseizure drug carbamazepine to its main in vivo metabolite, carbamazepine 10,11- epoxide [26]. Primidone (PRM, 5-ethylhexahydro-4,6-dioxo-5-phenylpyrimidine, Fig. 1 ) is an antiseizure drug that has been in use since the early 1950s. It is efficient for the treatment of partial and tonic–clonic seizures, although it also displays sedative action. PRM is converted into phenylethylmalondiamide (PEMA) and phenobarbital (FENO) by cytochrome P450 (CPY2C9/19) [27]. PEMA and FENO have pharmacological actions similar to those of the original compound, so these active metabolites maintain the therapeutic effect of PRM even after it has been metabolized. The synthesis of PEMA and FENO is of great importance because in many cases FENO is employed as a substitute for PRM [28,29]. Toxicity has been attributed to the metabolites generated from PRM. Studies on FENO have demonstrated its carcinogenic potential in rats [30], and the mitogenic activity of PEMA has been demonstrated in Salmonella [31]. This work reports on the oxidation of PRM in homogeneous medium by various oxidants, namely iodosylbenzene (PhIO), hydrogen peroxide, tert-butyl hydroperoxide (t-BOOH) and 3-chloroperoxybenzoic acid (m-CPBA), catalyzed by either a metalloporphyrin or the salen complex known as Jacobsen catalyst. These studies employing P450 models may help understand the mechanisms involved in xenobiotics degradation since they provide information about reaction selectivity and aid the characterization of potentially reactive and toxic metabolites. 2 Experimental 2.1 Materials and equipment PRM and FENO were purchased from Sigma–Aldrich Chemical Co. The Jacobsen catalyst Mn(salen) was purchased from Acros Oganics. The porphyrins 5,10,15,20-tetrakis-(pentafluorophenyl)porphyrin, H2(TFPP), and 5,10,15,20-tetrakis(4-carboxyphenyl)porphyrin, H2(TCPP), were acquired from Mid-Century. Iron and manganese insertions into these free base-porphyrins were carried out using the method of Adler et al. [32]. Fig. 2 shows the structures of the metalloporphyrins and the salen complex used in this study. tert-Butyl hydroperoxide, 70wt.% solution in water, and 3-chloroperoxybenzoic acid were acquired from Acros Oganics. Hydrogen peroxide (30% in water) was supplied by Fluka and stored at 5°C, and it was periodically titrated to confirm its purity. PhIO was obtained through iodosylbenzenediacetate hydrolysis [33], and its purity was measured by iodometric assay [33]. Acetonitrile (ACN) HPLC grade was purchased from Mallinckrodt. Water used in the experiments was purified by a Milli-Q, Millipore System. Imidazole was acquired from Acros Oganics. The HPLC analyses were performed on a SHIMADZU liquid chromatograph equipped with an LC-10AS solvent pump, an SPD-M 10A VP spectrophotometric detector coupled to a CTO-10A VP column oven, and an SCL-10A VP system controller. Separation of PRM and the oxidation products was carried out in a Lichrospher 100RP-18 column. GC–MS was performed using a QP2010 mass spectrometer (Shimadzu) fitted with a GC17A gas chromatograph (Shimadzu). The ionization voltage was 70eV. Gas chromatography was conducted in the temperature-programming mode, using a DB-5MS column (30m×0.25mm×0.25μm). Reaction products were identified by comparison of their retention times with known reference compounds, and by comparing their mass spectra to fragmentation patterns obtained from the NIST spectral library stored in the computer software (version 1.10 beta, Shimadzu) of the mass spectrometer. 2.2 Oxidation reactions Reactions were carried out in a 3mL vial containing a screw cap. Briefly, PRM (4.6mg, 2.1×10−5 mol) and the oxidant (PhIO, m-CPBA, t-BOOH or H2O2, 2.4×10−5 mol) in acetonitrile (2mL) were added to a vial containing the Jacobsen catalyst or the metalloporphyrins (6.0×10−7 mol) in acetonitrile (non-ionic catalyst) or aqueous medium (anionic catalyst). Reactions were carried out for 6h, under magnetic stirring at room temperature, at a catalyst/oxidant/drug molar ratio of 1:40:35, which was the standard condition in our studies. Another catalyst/oxidant/drug molar ratio was also used, namely 1:150:30 (excess oxidant conditions). Imidazole was added to some reactions, at a catalyst/axial ligand molar ratio of 1:10. The pH effect was investigated in buffered aqueous solution and acetonitrile 1:1 (2mL). Reactions at pH 2 were performed in phosphate buffer (H3PO4/NaH2PO4, 0.1molL−1); at pH 4 in acetate buffer (0.1molL−1); at pH 6-8 in phosphate buffer (NaH2PO4/Na2HPO4, 0.1molL−1); at pH 10 in ammonium buffer (NH4Cl/NH4OH). The pH of the reaction solution was adjusted by adding either HCl (0.5molL−1) or NaOH (0.5molL−1) solutions whenever necessary. At the end of the reaction, magnetic stirring was interrupted, and an aliquot of the reaction mixture (50μL) was withdrawn. After Mn(salen) or metalloporphyrin extraction, this aliquot was analyzed by high-performance liquid chromatography (HPLC). Mn(salen) and metalloporphyrin extraction was carried out by addition of hexane (500μL) and a mobile phase (500μL). The mixture was vortex-mixed and centrifuged; the aqueous phase (mobile phase) was then injected into the chromatographic system. This clean-up procedure did not remove unreacted PRM or the oxidation products. The oxidation products were identified by comparing their retention times with those of authentic PEMA and FENO standards. Yields are based on the added drug and were determined by a calibration curve. Other minor products were identified by mass spectrometry. Control reactions were carried out in the absence of catalyst, under the same conditions as the catalytic runs. No products were detected. 3 Results and discussion Primidone oxidation reactions were carried out in the presence of Mn(salen) or the metalloporphyrins Mn(TFPP)Cl, Mn(TCPP)Cl and Fe(TCPP)Cl (Fig. 2), which are commercially available second-generation metalloporphyrins well-established in the literature as good catalysts for hydrocarbon and drug oxidation [4,8–10,17]. The reactions were carried out in ACN, taking the solubility of the drug and its metabolites in this solvent into account. Solubility was also a determining factor for the choice of reaction conditions, once the studied substrate was a solid with limited solubility in the volume employed in the reactions (1.5mL). PhIO was firstly used as an oxygen donor because it is considered as a standard and simple oxidant which contains only one oxygen atom and is well-adapted for the selective and clean formation of metal-oxo intermediates [4]. The oxidation of PRM by PhIO led to the preferential formation of FENO (19%); only traces of PEMA and other unknown products were detected. FENO formation occurs via oxidation of the methylene group situated between two nitrogen atoms. The oxidation of this group takes place via an intermediate secondary alcohol in vivo [34]. This same intermediate can be postulated for the studied system, which would favor the cleavage of the pyrimidinic ring, with oxidative decarboxylation of the carbon located between the nitrogen atoms, thus generating PEMA in the same way as in the in vivo reactions (Fig. 1) [34]. m-CPBA, H2O2 and t-BOOH were also used as oxidants. These compounds may undergo heterolytic cleavage of the non-symmetrical O–O bond upon coordination to the salen or metalloporphyrin central metal ion, leading to the formation of the active species MnV(O)salen or MnIV(O)porp +. The situation can be also more complex because Mn(salen), like many transition metal complexes, can promote the homolytic cleavage of the O–O bond, leading to the formation of a less reactive intermediate, MnIV(OH)salen, as well as RO radicals, thus favoring the occurrence of radicalar mechanisms [4]. Since these intermediate species have different reactivities, the product yields obtained with these peroxides can account for the main mechanism the PRM oxidation goes through. Table 1 shows the results obtained in the oxidation of PRM by m-CPBA, t-BOOH or H2O2 catalyzed by the Jacobsen catalyst, after 6h of reaction. Contrary to what had been observed when PhIO was the oxidant, m-CPBA, t-BOOH and H2O2 generated PEMA in yields as high as 31%, as well as small quantities of FENO (Table 1). Besides FENO and PEMA, three other unknown products were also detected in the PRM oxidation by these peroxides, which were designated PD 1, PD 2 and PD 3, according to their order of elution, being PD1 the second most abundant (Table 1). The unknown products were isolated and analyzed by mass spectrometry (GC–MS). The mass spectrum of PD1 displayed an m/z signal at 163 and a fragmentation pattern corresponding to 2-phenylbutyramide (PBA) (Table 2 and Fig. 3 ). This product had already been identified by Foltz et al. as a minor PRM metabolite [35]. PD 2 displayed a peak at m/z 162 in the mass spectrum and a fragmentation pattern coincident with that of α-phenyl-γ-butyrolactone (BL) (Table 2 and Fig. 3), which had also been detected in patients with toxicity to PRM [36,37]. It was not possible to identify PD 3, since it was formed in amounts lower than the detection limit of the mass spectrometer. To investigate whether any of these products are formed through radicalar mechanisms, the catalytic activity of the Mn(salen)/t-BOOH system was evaluated in the absence of O2 (under argon atmosphere). Systems containing low dioxygen concentration should lead to a decrease in the amount of products generated from parallel radicalar reactions and an increase in the yields of products formed via the metal-oxo intermediate. t-BOOH was chosen as the standard oxidant for these studies because it tends to undergo homolytic cleavage of the peroxide O–O bond when it coordinates to the salen metal center. This homolytic cleavage is favored by the t-butyl groups, which donate electrons via an inductive effect, thus generating radicalar products [23]. There were no differences in the total yields obtained in reactions carried out in air or argon atmospheres. However, the product distribution depicted in Fig. 4 shows there was an increase in the yields of PEMA and a decrease in the amount of PBA for reactions in absence of O2. These results indicate that PBA is formed via a radicalar mechanism, initiated by the homolytic cleavage of the peroxide O–O bond and propagated by the O2 present in the reaction medium. Table 3 depicts the total yields (R (%)) obtained in the PRM reactions developed in the presence of excess of t-BOOH (catalyst/oxidant/substrate molar ratio=1:150:30). Fig. 5 shows the relative product distribution, as percentage. Excess t-BOOH resulted not only in higher total yields, as expected, but also in changes in the relative product distribution, as shown in Fig. 5. Excess t-BOOH caused an increase in PBA yields and a decrease in PEMA yields. This indicates that there may be additional oxidation of PEMA to PBA, favored by excess oxidant. The influence of nitrogen bases was also evaluated in PRM oxidation. Nitrogen ligands such as imidazole (Im) act as cocatalysts in systems involving Mn(salen) complexes, leading to a considerable increase in reaction speed, catalytic yields and selectivity [38]. The use of nitrogen ligands has three advantages: (i) they can coordinate to the Mn ion of the Mn(salen) complex in the position trans- to the metal-oxo bond, which stabilizes the active intermediate catalytic species MnV(O)salen [39] responsible for efficient, stereoselective oxidations; (ii) they prevent the fast reaction between MnV(O)salen and Mn(salen), which would result in the formation of the intermediate MnIV(O)salen, responsible for little efficient and poorly selective radicalar reactions [26,40]; (iii) they act as acid–base catalysts, favoring the heterolytic cleavage of the peroxide bond, thus leading to the desired intermediate MnV(O)salen [26,40]. Fig. 6 shows the graph for relative product distribution, as percentage, from the Mn(salen)-catalyzed PRM oxidation in both the presence and absence of imidazole, using t-BOOH as the oxygen donor. The presence of imidazole did not lead to any significant changes in the total yields of oxidized products from PRM (R =45% and 48%, in the absence and in the presence of imidazole, respectively). In terms of product distribution (Fig. 6), though, the catalytic results obtained in the presence of imidazole provided important information on reaction mechanism. Imidazole favored formation of the metabolite FENO, with concomitant decrease in the amounts of PEMA and PBA. The results reveal that PEMA and FENO are formed via distinct and competitive mechanisms, which involve different catalytically active species. The metabolite FENO is probably formed via the MnV(O)salen species, which is stabilized in the presence of the nitrogen ligand. As for PEMA, it may be formed via the intermediate MnIV(O)salen, generated from the reduction of the intermediate MnV(O)salen in the absence of imidazole, as discussed previously. Because PEMA and FENO are generated from the same intermediate in the in vivo metabolism (Fig. 1), and because literature reports state that the preparation of these compounds involves different pH conditions [34], the pH influence on product formation was investigated for the studied system. Fig. 7 gives evidence of the strong dependence of product distribution on pH. PBA was preferentially formed in acid media (pH 2 and 4), thus indicating that this product might be generated from the hydrolysis or decomposition of the PRM-OH intermediate in acidic conditions. FENO was obtained in larger quantities compared with PEMA, once acid media favors additional oxidation of the PRM-OH intermediate. As the pH increased, PEMA became the main reaction product, thus confirming that the alkaline hydrolysis of the PRM-OH intermediate is an important mechanism for PEMA formation. In terms of total yields, basic media favored higher PRM conversion (65% in pH 10 against 47% in pH 2). All these variable effects were also investigated using PhIO as oxidant. However, no differences in total product yield or product selectivity were observed, and FENO was the main product in all conditions. Control reactions carried out to investigate the Mn(salen)-catalyzed PEMA oxidation generated PBA as product. Another control reaction using Mn(salen) as catalyst and FENO as substrate led to BL as product. Therefore, PEMA is not generated from FENO degradation, and PEMA formation must compete with FENO production, as suggested previously. The results obtained in the present study led to the proposal of a reaction scheme (Fig. 8 ) for the Mn(salen)-catalyzed PRM oxidation, on the basis of the following observations: (i) PEMA and PBA are not formed when PhIO is employed as oxidant. (ii) In the case of the Mn(salen)/t-BOOH system, excess oxidant leads to increased PBA production, with concomitant decrease in the amounts of generated PEMA (Fig. 5). (iii) The presence of imidazole enhances selectivity toward FENO, together with a decrease in the amounts of PEMA and PBA (Fig. 6). (iv) Reactions in the absence of O2 result in increased PEMA and FENO production, with a reduction in PBA formation (Fig. 4). (v) Control reactions using PEMA as substrate lead to PBA as product. (vi) Control reactions using FENO as substrate produce BL; no PEMA is detected in this case. Taking observations (i) and (vi) into account, one can conclude that the metabolites PEMA and FENO are formed via distinct, competitive mechanisms. PhIO leads to the preferential formation of the active intermediate MnV(O)salen [41], while peroxides and peracids may result in two intermediates, depending on the type of O–O bond cleavage taking place (hemolytic or heterolytic) [26,42,43]. Evaluation of the variables affecting the system were carried out employing t-BOOH as oxidant, which mainly undergoes homolytic cleavage because of the presence of the electron-donating t-butyl groups (heterolytic cleavage takes place to a lesser extent). On the basis of observations (ii) and (v), one can conclude that PBA is formed via additional PEMA oxidation, once excess oxidant favors this reaction, with increased selectivity toward PBA. On the basis of observations (iii) and (iv), it is possible to propose that FENO is generated via the active species MnV(O)salen, since formation of this intermediate is favored in the presence of imidazole and under inert atmosphere [39,40]. On the other hand, PBA is produced via a radicalar mechanism, as a result of the homolytic cleavage of the O–O bond, thus leading to RO radicals, a reaction that is propagated by O2 present in the reaction medium. Formation of the active species MnV(O)salen depends on the heterolytic cleavage of the metal-oxo bond [42,43]. This species reacts with PRM, transferring its oxygen atom to the substrate, thus generating FENO (Fig. 8a). This product may undergo β-hydroxylation of the ethyl chain, followed by alcoholysis of the pyrimidinetrione ring. This should produce BL (Fig. 9 ), as observed by Al-Tarakji-Khalfhl et al. in natural systems [44]. Homolytic cleavage of the peroxide O–O bond should result in MnIV(OH)salen species and RO radicals, as well as other radicals. These radicals, together with the dioxygen present in the reaction medium produce PEMA. The latter product could undergo additional oxidation, to generate PBA (Fig. 8b). Metalloporphyrins were also employed as catalysts for PRM oxidation, for comparison purposes. Results depicted in Fig. 10 are given in terms of total product yield and selectivity; results shown in Fig. 11 concern product distribution. Mn(TFPP)Cl was the most efficient catalyst, since it led to 79% total product yield being 40% of FENO. The anionic metalloporphyrins Mn(TCPP)Cl and Fe(TCPP)Cl led to relatively low total product yield, 39% and 24%, respectively. This is probably due to the lower solubility of PRM in aqueous medium, where these anionic metallocomplexes are soluble. Except for Mn(TFPP)Cl, all the metallocomplexes studied in this work have a similar activity profile, with preferential PEMA formation; FENO, PBA and PD 3 were formed in lower amounts. Mn(TFPP)Cl also stood out among the other catalysts in terms of selectivity: it generated FENO as the main product, while PEMA and PBA were not detected. With respect to the metal ion, manganeseporphyrins were more efficient than the corresponding ironporphyrins, as reported for other systems [39]. The Jacobsen catalyst was less efficient than Mn(TFPP)Cl; however, the salen complex is cheap and easily prepared, besides being more selective toward PEMA, which is the main PRM metabolite in natural systems. 4 Conclusion This work has demonstrated the ability of the salen complex and metalloporphyrins to mimic the action of P450 in primidone oxidation, with formation of two of the metabolites found in the in vivo system: PEMA and FENO. The formation of these products is highly dependent on the oxidant, co-catalyst (Im), pH and dioxygen. To the best of our knowledge, this is the first report on the in vitro oxidative metabolism of primidone using metalloporphyrins and the salen complex as catalyst. Our studies have also revealed the potential application of these biomimetic chemical models in the synthesis of drug metabolites. This should provide samples for pharmacological tests, as well as aid studies that pursue the elucidation of in vivo drug metabolism, thus overcoming the difficulty in working with enzymes in vitro. Acknowledgements We thank FAPESP, CAPES and CNPq for financial support. We also acknowledge Dr. Cynthia Maria de Campos Prado Manso (Universidade de São Paulo, FFCLRP) for linguistic advice and Prof. Dr. Luiz A.B. de Moraes (Universidade de São Paulo, FFCLRP) for mass spectrometry measurements and technical help. References [1] A.Y.O. Matsuo E.P. Gallagher M. Trute P.L. Stapleton R. Levado D. Schlenk Comp. Biochem. Physiol. C 147 2008 78 [2] D.R. Livingstone Comp. Biochem. Physiol. A 120 1998 43 [3] K.M. Kleinow M.J. Melancon J.J. Lech. Environ. Health Perspect. 71 1987 105 [4] D. Mansuy C.R. Chim. 10 2007 392 [5] D. Kim M.J. Cryle J.J. De Voss P.R. Ortiz de Montellano Arch. Biochem. Biophys. 464 2007 213 [6] P.R.O. Montellano Cytochrome P450: Structure, Mechanism, and Biochemistry 3rd ed. 2004 Plenum Press New York [7] I.G. Denisov T.M. Makris S.G. Sligar I. Schlichting Chem. Rev. 105 2005 2253 [8] J.T. Groves J. Lee S.S. Marla J. Am. Chem. Soc. 119 1997 6269 [9] T.J. Hubin J.M. McCormick S.R. Collinson M. Buchalova C.M. Perkins N.W. Alcock P.K. Kahol A. Raghunathan D.H. Busch J. Am. Chem. Soc. 122 2000 2512 [10] A.L. Faria T.C.O. Mac Leod M.D. Assis Catal. Today 133–135 2008 863 [11] M.S. Chorghade D.R. Hill E.C. Lee R.J. Pariza D.H. Dolphin F. Hino L.Y. Zhang Pure Appl. Chem. 68 1996 753 [12] M. Vidal M. Bonnafous S. Defrance P. Loiseau J. Bernadou B. Meunier Drug Metab. Dispos. 21 1993 811 [13] J. Bernadou M. Bonnafous G. Labat P. Loiseau B. Meunier Drug Metab. Dispos. 19 1991 360 [14] A.C.M.A. Santos J.R.L. Smith M.D. Assis J. Porph. Phthalocyan. 09 2005 326 [15] M. Komuro T. Higuchi M. Hirobe J. Chem. Soc., Perkin Trans. I 18 1996 2309 [16] A.J.B. Melo Y. Iamamoto A.P.J. Maestrin J.R.L. Smith M.D. Santos N.P. Lopes P.S. Bonato J. Mol. Catal. A: Chem. 226 2005 23 [17] J. Bernadou B. Meunier Adv. Synth. Catal. 346 2004 171 [18] E.N. Jacobsen W. Zhang A.R. Muci J.R. Ecker L. Deng. J. Am. Soc. 113 1991 7063 [19] S. Yan D. Klemm Tetrahedron 58 2002 10065 [20] T. Katsuki J. Mol. Catal. A: Chem. 113 1996 87 [21] T. Katsuki Coord. Chem. Rev. 140 1995 189 [22] R. Irie K. Noda Y. Ito N. Matsumoto T. Katsuki Tetrahedron Asymmetry 2 1991 481 [23] T.C.O. Mac Leod D.F.C. Guedes M.R. Lelo R.A. Rocha B.L. Caetano K.J. Ciuffi M.D. Assis J. Mol. Catal. A: Chem. 259 2006 319 [24] V. Mirkhani M. Moghadam S. Tangestaninejad H. Kargar Appl. Catal. A: Gen. 303 2006 221 [25] H.B. Gray A. Bottcher M.W. Grinstaff J.A. Labinger J. Mol. Catal. A: Chem. 113 1996 191 [26] T.C.O. Mac Leod V.P. Barros A.L. Faria M.A. Schiavon I.V.P. Yoshida M.E.C. Queiroz M.D. Assis J. Mol. Catal. A: Chem. 273 2007 259 [27] R. Mandrioli F. Albani G. Casamenti C. Sabbioni M.A. Raggi J. Chromatogr. B 762 2001 109 [28] J. Konsil J. Pharm. Sci. 5 2002 169 [29] V. Ferranti C. Chabenat S. Menager O. Lafont J. Chromatogr. B 718 1998 199 [30] P. Gareri T. Gravina G. Ferreri G. De Sarro Progr. Neurobiol. 58 1999 389 [31] H.A. El Masri C.J. Portier Drug Metab. Dispos. 26 1998 585 [32] A.D. Adler F.R. Longo F. Kampas J. Kim J. Inorg. Nucl. Chem. 32 1970 2443 [33] J.G. Sharefkin H. Saltzmann Org. Synth. 43 1963 62 [34] O. Lafont C. Cavé S. Ménager M. Miocque Eur. J. Med. Chem. 25 1990 61 [35] R.L. Foltz M.W. Couch M. Greer K.N. Scott C.M. Williams Biochem. Med. 6 1972 294 [36] B.D. Andresen F.T. Davis J.L. Templeton R.H. Hammer H.L. Panzik Res. Commun. Chem. Pathol. Pharmacol. 15 1976 21 [37] B.D. Andresen F.T. Davis J.L. Templeton H.L. Panzik R.H. Hammer Res. Commun. Chem. Pathol. Pharmacol. 18 1977 439 451 [38] B. Meunier Chem. Rev. 92 1992 1411 [39] M.J. Gunter P. Turner J. Mol. Catal. 66 1991 121 [40] P. Battioni J.P. Renaud J.F. Bartoli M.R. Artiles M. Fort D. Mansuy J. Am. Chem. Soc. 110 1988 8462 [41] N.S. Venkataramanan G. Kuppuraj S. Rajagopal Coord. Chem. Rev. 249 2005 1249 [42] W. Nam H.J. Han S. Oh Y.J. Lee M. Choi S. Han C. Kim S.K. Woo W. Shin. J. Am. Chem. Soc. 122 2000 8677 [43] W. Nam H.J. Choi H.J. Han S.H. Cho H.J. Lee S. Han. Chem. Commun. 1999 387 [44] Y. Al-Tarakji-Khalfhl C. Cavé S. Ménager Y. Legras C.C. Famoux O. Lafont Eur. J. Med. Chem. 28 1993 593",
      "scopus-id": "55549117092",
      "coredata": {
        "eid": "1-s2.0-S1381116908004007",
        "dc:description": "Primidone (PRM) oxidation by various oxidants such as iodosylbenzene (PhIO), tert-butyl hydroperoxide 70wt.% (t-BOOH), 3-chloroperoxybenzoic acid (m-CPBA) and hydrogen peroxide 30wt.%, mediated by either a salen complex or metalloporphyrins, was investigated. The catalytic systems led to phenylethylmalondiamide (PEMA) and phenobarbital (FENO), the same metabolites obtained in vivo with P450 enzymes, although three other products were also detected. Product formation was highly dependent on the oxidant, co-catalyst (imidazole), pH and dioxygen. These biomimetic chemical models have potential application in the synthesis of drug metabolites, which should provide samples for pharmacological tests. They can also be employed in studies that pursue the elucidation of in vivo drug metabolism.",
        "openArchiveArticle": "false",
        "prism:coverDate": "2008-12-10",
        "openaccessUserLicense": null,
        "prism:aggregationType": "Journal",
        "prism:url": "https://api.elsevier.com/content/article/pii/S1381116908004007",
        "dc:creator": [
          {
            "@_fa": "true",
            "$": "Mac Leod, T.C.O."
          },
          {
            "@_fa": "true",
            "$": "Faria, A.L."
          },
          {
            "@_fa": "true",
            "$": "Barros, V.P."
          },
          {
            "@_fa": "true",
            "$": "Queiroz, M.E.C."
          },
          {
            "@_fa": "true",
            "$": "Assis, M.D."
          }
        ],
        "link": [
          {
            "@_fa": "true",
            "@rel": "self",
            "@href": "https://api.elsevier.com/content/article/pii/S1381116908004007"
          },
          {
            "@_fa": "true",
            "@rel": "scidir",
            "@href": "https://www.sciencedirect.com/science/article/pii/S1381116908004007"
          }
        ],
        "dc:format": "application/json",
        "openaccessType": null,
        "pii": "S1381-1169(08)00400-7",
        "prism:volume": "296",
        "prism:publisher": "Elsevier B.V.",
        "dc:title": "Primidone oxidation catalyzed by metalloporphyrins and Jacobsen catalyst",
        "prism:copyright": "Copyright © 2008 Elsevier B.V. All rights reserved.",
        "openaccess": "0",
        "prism:issn": "13811169",
        "prism:issueIdentifier": "1-2",
        "dcterms:subject": [
          {
            "@_fa": "true",
            "$": "Primidone"
          },
          {
            "@_fa": "true",
            "$": "Salen complex"
          },
          {
            "@_fa": "true",
            "$": "Metalloporphyrin"
          },
          {
            "@_fa": "true",
            "$": "Catalysis"
          },
          {
            "@_fa": "true",
            "$": "Biomimetic models"
          },
          {
            "@_fa": "true",
            "$": "Jacobsen catalyst"
          }
        ],
        "openaccessArticle": "false",
        "prism:publicationName": "Journal of Molecular Catalysis A: Chemical",
        "prism:number": "1-2",
        "openaccessSponsorType": null,
        "prism:pageRange": "54-60",
        "prism:endingPage": "60",
        "pubType": "fla",
        "prism:coverDisplayDate": "10 December 2008",
        "prism:doi": "10.1016/j.molcata.2008.09.008",
        "prism:startingPage": "54",
        "dc:identifier": "doi:10.1016/j.molcata.2008.09.008",
        "openaccessSponsorName": null
      },
      "objects": {
        "object": [
          {
            "@category": "standard",
            "@height": "201",
            "@width": "376",
            "@_fa": "true",
            "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1381116908004007-gr4.jpg?httpAccept=%2A%2F%2A",
            "@multimediatype": "JPEG image file",
            "@type": "IMAGE-DOWNSAMPLED",
            "@size": "17703",
            "@ref": "gr4",
            "@mimetype": "image/jpeg"
          },
          {
            "@category": "thumbnail",
            "@height": "67",
            "@width": "125",
            "@_fa": "true",
            "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1381116908004007-gr4.sml?httpAccept=%2A%2F%2A",
            "@multimediatype": "GIF image file",
            "@type": "IMAGE-THUMBNAIL",
            "@size": "1891",
            "@ref": "gr4",
            "@mimetype": "image/gif"
          },
          {
            "@category": "standard",
            "@height": "200",
            "@width": "376",
            "@_fa": "true",
            "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1381116908004007-gr5.jpg?httpAccept=%2A%2F%2A",
            "@multimediatype": "JPEG image file",
            "@type": "IMAGE-DOWNSAMPLED",
            "@size": "22237",
            "@ref": "gr5",
            "@mimetype": "image/jpeg"
          },
          {
            "@category": "thumbnail",
            "@height": "66",
            "@width": "125",
            "@_fa": "true",
            "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1381116908004007-gr5.sml?httpAccept=%2A%2F%2A",
            "@multimediatype": "GIF image file",
            "@type": "IMAGE-THUMBNAIL",
            "@size": "2189",
            "@ref": "gr5",
            "@mimetype": "image/gif"
          },
          {
            "@category": "standard",
            "@height": "190",
            "@width": "376",
            "@_fa": "true",
            "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1381116908004007-gr6.jpg?httpAccept=%2A%2F%2A",
            "@multimediatype": "JPEG image file",
            "@type": "IMAGE-DOWNSAMPLED",
            "@size": "18218",
            "@ref": "gr6",
            "@mimetype": "image/jpeg"
          },
          {
            "@category": "thumbnail",
            "@height": "63",
            "@width": "125",
            "@_fa": "true",
            "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1381116908004007-gr6.sml?httpAccept=%2A%2F%2A",
            "@multimediatype": "GIF image file",
            "@type": "IMAGE-THUMBNAIL",
            "@size": "1652",
            "@ref": "gr6",
            "@mimetype": "image/gif"
          },
          {
            "@category": "standard",
            "@height": "199",
            "@width": "376",
            "@_fa": "true",
            "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1381116908004007-gr7.jpg?httpAccept=%2A%2F%2A",
            "@multimediatype": "JPEG image file",
            "@type": "IMAGE-DOWNSAMPLED",
            "@size": "23096",
            "@ref": "gr7",
            "@mimetype": "image/jpeg"
          },
          {
            "@category": "thumbnail",
            "@height": "66",
            "@width": "125",
            "@_fa": "true",
            "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1381116908004007-gr7.sml?httpAccept=%2A%2F%2A",
            "@multimediatype": "GIF image file",
            "@type": "IMAGE-THUMBNAIL",
            "@size": "2331",
            "@ref": "gr7",
            "@mimetype": "image/gif"
          },
          {
            "@category": "standard",
            "@height": "203",
            "@width": "368",
            "@_fa": "true",
            "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1381116908004007-gr10.jpg?httpAccept=%2A%2F%2A",
            "@multimediatype": "JPEG image file",
            "@type": "IMAGE-DOWNSAMPLED",
            "@size": "17423",
            "@ref": "gr10",
            "@mimetype": "image/jpeg"
          },
          {
            "@category": "thumbnail",
            "@height": "69",
            "@width": "125",
            "@_fa": "true",
            "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1381116908004007-gr10.sml?httpAccept=%2A%2F%2A",
            "@multimediatype": "GIF image file",
            "@type": "IMAGE-THUMBNAIL",
            "@size": "1732",
            "@ref": "gr10",
            "@mimetype": "image/gif"
          },
          {
            "@category": "standard",
            "@height": "200",
            "@width": "376",
            "@_fa": "true",
            "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1381116908004007-gr11.jpg?httpAccept=%2A%2F%2A",
            "@multimediatype": "JPEG image file",
            "@type": "IMAGE-DOWNSAMPLED",
            "@size": "23648",
            "@ref": "gr11",
            "@mimetype": "image/jpeg"
          },
          {
            "@category": "thumbnail",
            "@height": "66",
            "@width": "125",
            "@_fa": "true",
            "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1381116908004007-gr11.sml?httpAccept=%2A%2F%2A",
            "@multimediatype": "GIF image file",
            "@type": "IMAGE-THUMBNAIL",
            "@size": "2421",
            "@ref": "gr11",
            "@mimetype": "image/gif"
          },
          {
            "@category": "standard",
            "@height": "263",
            "@width": "508",
            "@_fa": "true",
            "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1381116908004007-gr1.gif?httpAccept=%2A%2F%2A",
            "@multimediatype": "GIF image file",
            "@type": "IMAGE-DOWNSAMPLED",
            "@size": "9986",
            "@ref": "gr1",
            "@mimetype": "image/gif"
          },
          {
            "@category": "thumbnail",
            "@height": "65",
            "@width": "125",
            "@_fa": "true",
            "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1381116908004007-gr1.sml?httpAccept=%2A%2F%2A",
            "@multimediatype": "GIF image file",
            "@type": "IMAGE-THUMBNAIL",
            "@size": "1257",
            "@ref": "gr1",
            "@mimetype": "image/gif"
          },
          {
            "@category": "standard",
            "@height": "485",
            "@width": "659",
            "@_fa": "true",
            "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1381116908004007-gr2.gif?httpAccept=%2A%2F%2A",
            "@multimediatype": "GIF image file",
            "@type": "IMAGE-DOWNSAMPLED",
            "@size": "14148",
            "@ref": "gr2",
            "@mimetype": "image/gif"
          },
          {
            "@category": "thumbnail",
            "@height": "92",
            "@width": "125",
            "@_fa": "true",
            "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1381116908004007-gr2.sml?httpAccept=%2A%2F%2A",
            "@multimediatype": "GIF image file",
            "@type": "IMAGE-THUMBNAIL",
            "@size": "1283",
            "@ref": "gr2",
            "@mimetype": "image/gif"
          },
          {
            "@category": "standard",
            "@height": "120",
            "@width": "602",
            "@_fa": "true",
            "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1381116908004007-gr3.gif?httpAccept=%2A%2F%2A",
            "@multimediatype": "GIF image file",
            "@type": "IMAGE-DOWNSAMPLED",
            "@size": "6427",
            "@ref": "gr3",
            "@mimetype": "image/gif"
          },
          {
            "@category": "thumbnail",
            "@height": "25",
            "@width": "125",
            "@_fa": "true",
            "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1381116908004007-gr3.sml?httpAccept=%2A%2F%2A",
            "@multimediatype": "GIF image file",
            "@type": "IMAGE-THUMBNAIL",
            "@size": "671",
            "@ref": "gr3",
            "@mimetype": "image/gif"
          },
          {
            "@category": "standard",
            "@height": "171",
            "@width": "753",
            "@_fa": "true",
            "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1381116908004007-gr8.gif?httpAccept=%2A%2F%2A",
            "@multimediatype": "GIF image file",
            "@type": "IMAGE-DOWNSAMPLED",
            "@size": "7410",
            "@ref": "gr8",
            "@mimetype": "image/gif"
          },
          {
            "@category": "thumbnail",
            "@height": "28",
            "@width": "125",
            "@_fa": "true",
            "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1381116908004007-gr8.sml?httpAccept=%2A%2F%2A",
            "@multimediatype": "GIF image file",
            "@type": "IMAGE-THUMBNAIL",
            "@size": "536",
            "@ref": "gr8",
            "@mimetype": "image/gif"
          },
          {
            "@category": "standard",
            "@height": "137",
            "@width": "719",
            "@_fa": "true",
            "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1381116908004007-gr9.gif?httpAccept=%2A%2F%2A",
            "@multimediatype": "GIF image file",
            "@type": "IMAGE-DOWNSAMPLED",
            "@size": "6814",
            "@ref": "gr9",
            "@mimetype": "image/gif"
          },
          {
            "@category": "thumbnail",
            "@height": "24",
            "@width": "125",
            "@_fa": "true",
            "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1381116908004007-gr9.sml?httpAccept=%2A%2F%2A",
            "@multimediatype": "GIF image file",
            "@type": "IMAGE-THUMBNAIL",
            "@size": "578",
            "@ref": "gr9",
            "@mimetype": "image/gif"
          },
          {
            "@category": "standard",
            "@height": "105",
            "@width": "448",
            "@_fa": "true",
            "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1381116908004007-fx1.gif?httpAccept=%2A%2F%2A",
            "@multimediatype": "GIF image file",
            "@type": "IMAGE-DOWNSAMPLED",
            "@size": "3440",
            "@ref": "fx1",
            "@mimetype": "image/gif"
          },
          {
            "@category": "thumbnail",
            "@height": "51",
            "@width": "219",
            "@_fa": "true",
            "$": "https://api.elsevier.com/content/object/eid/1-s2.0-S1381116908004007-fx1.sml?httpAccept=%2A%2F%2A",
            "@multimediatype": "GIF image file",
            "@type": "IMAGE-THUMBNAIL",
            "@size": "1193",
            "@ref": "fx1",
            "@mimetype": "image/gif"
          }
        ]
      },
      "link": {
        "@rel": "abstract",
        "@href": "https://api.elsevier.com/content/abstract/scopus_id/55549117092"
      }
    }
  }
}